Holden SE - Search Results

1

How many people inject insulin? UK estimates from 1991 to 2010.

Holden SE, Gale EA, Jenkins-Jones S, Currie CJ. Holden SE, et al. Diabetes Obes Metab. 2014 Jun;16(6):553-9. doi: 10.1111/dom.12260. Epub 2014 Feb 9. Diabetes Obes Metab. 2014. PMID: 24410846

2

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.

Holden SE, Poole CD, Morgan CL, Currie CJ. Holden SE, et al. BMJ Open. 2011 Jan 1;1(2):e000258. doi: 10.1136/bmjopen-2011-000258. BMJ Open. 2011. PMID: 22021891 Free PMC article.

3

Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities.

Holden SE, Currie CJ. Holden SE, et al. Atherosclerosis. 2012 May;222(1):26-8. doi: 10.1016/j.atherosclerosis.2012.01.052. Epub 2012 Feb 14. Atherosclerosis. 2012. PMID: 22387058 No abstract available.

4

The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010).

Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ. Holden SE, et al. Child Adolesc Psychiatry Ment Health. 2013 Oct 11;7(1):34. doi: 10.1186/1753-2000-7-34. Child Adolesc Psychiatry Ment Health. 2013. PMID: 24119376 Free PMC article.

5

Mortality risk with sulphonylureas compared to metformin.

Holden SE, Currie CJ. Holden SE, et al. Diabetes Obes Metab. 2014 Oct;16(10):885-90. doi: 10.1111/dom.12280. Epub 2014 Mar 14. Diabetes Obes Metab. 2014. PMID: 24533964

6

Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Morgan CL, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):957-62. doi: 10.1111/dom.12302. Epub 2014 May 8. Diabetes Obes Metab. 2014. PMID: 24720708

7

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Morgan CL, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):977-83. doi: 10.1111/dom.12306. Epub 2014 May 22. Diabetes Obes Metab. 2014. PMID: 24762119

8

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs.

Holden SE, Bannister CA, Currie CJ. Holden SE, et al. Diabetologia. 2014 Sep;57(9):2001-2. doi: 10.1007/s00125-014-3281-1. Epub 2014 Jun 3. Diabetologia. 2014. PMID: 24891018 No abstract available.

9

Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.

Currie CJ, Holden SE. Currie CJ, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):881-4. doi: 10.1111/dom.12349. Diabetes Obes Metab. 2014. PMID: 25040702 No abstract available.

10

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.

Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ. Bannister CA, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Nov;16(11):1165-73. doi: 10.1111/dom.12354. Epub 2014 Jul 31. Diabetes Obes Metab. 2014. PMID: 25041462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page